Skip to content
Open in App
BioNTech SE logo

BioNTech SE

web2

BioNTech SE, together with its subsidiaries, engages in the development and commercialization o...

Symbol · 22UAY
Company profile

About

BioNTech SE, together with its subsidiaries, engages in the development and commercialization of immunotherapies in Germany. The company offers BNT162, an mRNA vaccine for the treatment of SARS-CoV-2 virus. It also develops oncology drugs under Phase III clinical trial, including Gotistobart for metastatic non-small cell lung cancer, Pumitamig for small cell lung cancer and advanced/metastatic triple-negative breast cancer, and Trastuzumab pamirtecan for metastatic breast cancer and epirubicin and cyclophosphamide; and drugs under Phase 2/3 clinical trial, such as BNT113 for human papillomavirus and head and neck squamous cell carcinoma, as well as Pumitamig for metastatic colorectal and non-small cell lung cancer. In addition, the company engages in the development of oncology drugs under Phase II clinical trial comprising BNT116 for advance non-small cell lung cancer, BNT326/YL202 for multiple solid tumors and advanced/metastatic breast cancer, Autogene cevumeran for advance colorectal cancer, and Gotistobart for platinum-resistant ovarian cancer, as well as Pumitamig for glioblastoma, hepatocellular carcinoma, malignant pleural mesothelioma, neuroendocrine neoplasms, and metastatic pancreatic ductal adenocarcinoma. Further, it develops BNT166 which is Phase II clinical trial for mpox virus; and infectious diseases drugs under Phase 1/2 clinical trial, which include BNT162 + BNT161 for SARS-CoV-2 and influenza, BNT164 for tuberculosis, BNT165 for malaria, and BNT166 for mpox. The company was incorporated in 2008 and is headquartered in Mainz, Germany.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

People

Company team

IL

Iris Low-Friedrich

Member of Supervisory Board

Company leadership profile.

HW

Helmut W. Jeggle

Independent Supervisory Board Chairman

Company leadership profile.

UW

Ulrich Wandschneider

Independent Deputy Chairman Supervisory Board

Company leadership profile.

AM

Anja Morawietz

Supervisory Board Member

Company leadership profile.

RS

Rudolf Staudigl

Supervisory Board Member

Company leadership profile.

MM

Michael Motschmann

Independent Supervisory Board Member

Company leadership profile.

NB

Nicola Blackwood

Member of Supervisory Board

Company leadership profile.

SS

Susanne Schaffert

Member of Supervisory Board

Company leadership profile.

Expert coverage

1 expert evaluated BioNTech SE.

Orbitrum research

Experts evaluating BioNTech SE

Explore the public profiles of experts who have evaluated this project.

Orbitrum Academy

Learn how to read a project assessment